Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
October 07, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)...
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
October 06, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)...
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
August 30, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
August 10, 2021 16:05 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
August 09, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of...
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting
June 10, 2021 08:30 ET
|
Acer Therapeutics Inc.
Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission...
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
May 25, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and...
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
May 17, 2021 16:01 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
March 29, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Notice of Settlement of Derivative Suits
March 25, 2021 16:05 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS DAVID GIROUX, Derivatively on Behalf of ACER THERAPEUTICS, INC., ...